Proteostasis Therapeutics (NASDAQ:PTI)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Tuesday, December 19th. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 186.26% from the stock’s current price.
PTI has been the subject of several other reports. Robert W. Baird lifted their target price on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. Finally, Leerink Swann lifted their target price on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $16.00.
Proteostasis Therapeutics (NASDAQ PTI) traded down $0.22 during trading on Tuesday, reaching $5.24. The company’s stock had a trading volume of 1,350,000 shares, compared to its average volume of 2,200,000. The company has a market cap of $173.51 and a PE ratio of -2.37. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $16.67.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.16. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.38 million. research analysts forecast that Proteostasis Therapeutics will post -2.47 earnings per share for the current fiscal year.
In other Proteostasis Therapeutics news, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $4.88, for a total transaction of $2,459,651.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Franklin M. Berger bought 60,000 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were bought at an average price of $5.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the director now owns 266,162 shares in the company, valued at approximately $1,330,810. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 2,100,000 shares of company stock valued at $10,500,000. 17.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new stake in Proteostasis Therapeutics during the 2nd quarter valued at $254,000. Jennison Associates LLC grew its position in shares of Proteostasis Therapeutics by 6.2% during the 2nd quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after acquiring an additional 120,575 shares during the period. FMR LLC grew its position in shares of Proteostasis Therapeutics by 2.3% during the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after acquiring an additional 66,111 shares during the period. Bain Capital Public Equity Management LLC bought a new stake in shares of Proteostasis Therapeutics during the 2nd quarter valued at $1,233,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Proteostasis Therapeutics during the 2nd quarter valued at $296,000. Institutional investors and hedge funds own 51.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/proteostasis-therapeutics-pti-buy-rating-reaffirmed-at-hc-wainwright.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.